Dikshit Madhu

Dikshit has made significant contributions to molecular pharmacology with special emphasis on redox/NO biology and metabolism. In the area of neutrophil biology she enhanced our understanding of how nitric oxide modulates neutrophil differentiation, survival, free radical generation, NETosis, chemotaxis, and microbicidal activity. She has investigated the role of iNOS in metabolic regulations and insulin sensitivity. She led the anti-thrombotic drug discovery team at Central Drug Research Institute, and one of their new chemical entities has received permission for phase I clinical trial in India. She initiated a programme on drug and biomarker discovery in the area of fatty liver disease at the Translational Health Science and Technology Institute, with significant contributions. During the COVID-19 pandemic, under a Department of Biotechnology - Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy (AYUSH) project, she undertook preclinical and pharmacokinetic evaluations of AYUSH herbal formulations for mitigating SARS- CoV2 and associated pathologies. Dikshit has published 200+ papers, 23 reviews, and 8 patents, edited 3 books, and has supervised 37 PhD and 10 MD theses.